NCT00560352View on ClinicalTrials.gov

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Multiple Myeloma
Interventions
DRUG

Dasatinib

Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD

DRUG

Bortezomib

Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD

DRUG

Dexamethasone

Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD

Trial Locations (7)

30322

Winship Cancer Institute, Emory University, Atlanta

32806

Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando

37007

Local Institution, Salamanca

40138

Local Institution, Bologna

44093

Local Institution, Nantes

59037

Local Institution, Lille

70124

Local Institution, Bari

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY